Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis

References

• Fanouriakis A, Tziolos N, Bertsias G, et al. Update Omicron the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):1–12.
   Web of Science ®Google Scholar
• Ward MM. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996–2004. J Rheumatol. 2009;36(1):63–67.
   PubMed Web of Science ®Google Scholar
• Cassia M, Alberici F, Gallieni M, et al. Lupus nephritis and B-cell targeting therapy. Expert Rev Clin Immunol. 2017;13(10):951–962.
   PubMed Web of Science ®Google Scholar
• Mahajan A, Amelio J, Gairy K, et al. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020;29(9):1011–1020.
   PubMed Web of Science ®Google Scholar
• Parodis I, Stockfelt M, Sjowall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne). 2020;7:316.
   PubMed Web of Science ®Google Scholar
• Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012;30(1):69–77.
   PubMed Web of Science ®Google Scholar
• Ruiz-Irastorza G, Bertsias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. Rheumatology (Oxford). 2020;59(5):v69–v81.
   PubMedGoogle Scholar
• Plüß M, Tampe B, Niebusch N, et al. Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med (Lausanne). 2020;7:222.
   PubMed Web of Science ®Google Scholar
• Sciascia S, Radin M, Yazdany J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2017;16(3):287–293.
   PubMed Web of Science ®Google Scholar
• Parodis I, Vital EM, Hassan SU, et al. De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford). 2021;60(9):4348–4354.
   PubMed Web of Science ®Google Scholar
• Brådland S, Andel P, Diamandopoulos A, et al. Pos1451 developing a tool to measure the learning curve: enthesitis ultrasound in psoriasis arthritis. Ann Rheum Dis. 2021;80(1):1009.2–1010.
   Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63–72.
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-Year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383(12):1117–1128.
   PubMed Web of Science ®Google Scholar
• Sjowall C, Coster L. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scand J Rheumatol. 2014;43(5):428–430.
   PubMed Web of Science ®Google Scholar
• Hui-Yuen JS, Reddy A, Taylor J, et al. Safety and efficacy of belimumab to treat systemic lupus erythematosus in academic clinical practices. J Rheumatol. 2015;42(12):2288–2295.
   PubMed Web of Science ®Google Scholar
• Staveri C, Karokis D, Liossis SC. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Semin Arthritis Rheum. 2017;46(6):788–790.
   PubMed Web of Science ®Google Scholar
• Anjo C, Mascaro JM, Jr., Espinosa G, et al. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting. Scand J Rheumatol. 2019;48(6):469–473.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Guide to the contents of a cochrane protocol and review. 2008. p. 51–79. (Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series).
   Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two–week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69(5):1016–1027.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Bass D, Chu M, et al. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: a subgroup analysis from a phase 3 randomized placebo-controlled trial. Mod Rheumatol. 2020;30(2):313–320.
   PubMed Web of Science ®Google Scholar
• Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol. 2021;73(1):121–131.
   PubMed Web of Science ®Google Scholar
• Ginzler E, Guedes Barbosa LS, D’Cruz D, et al. Phase III/IV, randomized, Fifty-Two-Week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol. 2022;74(1):112–123.
   PubMed Web of Science ®Google Scholar
• Kang S, Fedoriw Y, Brenneman EK, et al. BAFF induces tertiary lymphoid structures and positions T cells within the glomeruli during lupus nephritis. J Immunol. 2017;198(7):2602–2611.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Schneider P, et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol. 2014;10(6):365–373.
   PubMed Web of Science ®Google Scholar
• Liu Z, Davidson A. BAFF and selection of autoreactive B cells. Trends Immunol. 2011;32(8):388–394.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–233.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–1226.
   PubMed Web of Science ®Google Scholar
• Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12(6):367–372.
   PubMed Web of Science ®Google Scholar
• Kraaij T, Arends EJ, van Dam LS, et al. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant. 2021;36(8):1474–1483.
   PubMed Web of Science ®Google Scholar
• Kraaij T, Huizinga TWJ, Rabelink TJ, et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology. 2014;53(11):2122–2124.
   PubMed Web of Science ®Google Scholar
• Simonetta F, Allali D, Roux-Lombard P, et al. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine. 2017;84(2):235–236.
   PubMed Web of Science ®Google Scholar
• Hassan SU, Md Yusof MY, Emery P, et al. Biologic sequencing in systemic lupus erythematosus: after secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab. Front Med (Lausanne). 2020;7:498.
   PubMed Web of Science ®Google Scholar
• Ward M, Tektonidou MG. Belimumab as add-on therapy in lupus nephritis. N Engl J Med. 2020;383(12):1184–1185.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Dasgupta A, Ward MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and bayesian meta-analysis. Arthritis Rheumatol. 2016;68(6):1432–1441.
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang S, Chen T, et al. Machine learning for prediction and risk stratification of lupus nephritis renal flare. Am J Nephrol. 2021;52(2):152–160.
   PubMed Web of Science ®Google Scholar
• Parikh SV, Nagaraja HN, Hebert L, et al. Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol. 2014;9(2):279–284.
   PubMed Web of Science ®Google Scholar
• Binda V, Trezzi B, Del Papa N, et al. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). J Nephrol. 2020;33(5):1019–1025.
   PubMed Web of Science ®Google Scholar
• Liu D, Zhou Q, Wang D, et al. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy. Lupus. 2022;31(12):1456–1467.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zeng M, Ge Y, et al. Effectiveness and safety of belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: a case report and literature review. Front Immunol. 2022;13:977377.
   PubMed Web of Science ®Google Scholar
• Singh JA, Shah NP, Mudano AS. Belimumab for systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;2(2):CD010668.
   PubMedGoogle Scholar
• Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins lupus cohort. Lupus Sci Med. 2015;2(1):e000066.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Navarra S, Petri MA, et al. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013;22(2):144–154.
   PubMed Web of Science ®Google Scholar
• Wise LM, Stohl W. The safety of belimumab for the treatment of systemic lupus erythematosus. Expert Opin Drug Saf. 2019; 18(12):1133–1144.
   PubMed Web of Science ®Google Scholar